Henry Schein upgraded by Robert W. Baird with a new price target
$HSIC
Medical Specialities
Health Care
Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $92.00 from $81.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $80.00 | Equal Weight | Wells Fargo |
| 1/6/2025 | $69.00 → $84.00 | Underperform → Buy | BofA Securities |
| 12/4/2024 | $75.00 | Neutral | Mizuho |
| 7/22/2024 | $81.00 → $92.00 | Neutral → Outperform | Robert W. Baird |
| 2/26/2024 | $78.00 | Market Perform | Leerink Partners |
| 12/12/2023 | $71.00 → $82.00 | Neutral → Overweight | JP Morgan |
| 11/10/2023 | $70.00 | Hold → Buy | Stifel |
| 8/8/2022 | $80.00 | Sell → Neutral | UBS |
SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
SC 13G - HENRY SCHEIN INC (0001000228) (Subject)
SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
10-Q - HENRY SCHEIN INC (0001000228) (Filer)
8-K - HENRY SCHEIN INC (0001000228) (Filer)
DEFA14A - HENRY SCHEIN INC (0001000228) (Filer)
First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re
Fifth Annual Award Spotlights Up-and-Coming Athletic Trainers Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (NASDAQ:HSIC), announced today that Ian Jeffer, MS, ATC, LAT, Head Athletic Trainer at Desert Ridge High School in Mesa, Arizona, is the winner of the fifth annual Henry Schein Medical Athletics and Schools Rising Star Award. The recognition celebrates emerging athletic trainers with up to five years of experience in the Sports Medicine industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250418934421/en/From left to right: Ian Jeffer, Marissa Lucas, and Angel Picart. Mr. Jeffer was recognized f
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on
First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on
Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result
Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00
BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously
Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
The American Dental Association Foundation's Initiative, with Exclusive National Sponsors Henry Schein and Colgate-Palmolive, Continues to Expand Its Reach, With Nearly 325,500 Children Expected to Receive Care Throughout 2025 The American Dental Association Foundation (ADA Foundation) is celebrating the 23rd year of its Give Kids A Smile® (GKAS) program, which officially launched on Friday, February 7, at the 2025 national kick-off event at Meharry Medical College School of Dentistry. Since its national launch in 2003, GKAS volunteers have provided free oral health education and services to more than 9.5 million underserved children in the U.S. This press release features multimedia. Vi